{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.5","upperLimit":"62.8","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 178 weeks","title":"Part 2 - Percentage of Participants With Clinical Benefit Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}